Kyverna Therapeutics (NASDAQ:KYTX) Earns Neutral Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Kyverna Therapeutics (NASDAQ:KYTX) in a research report released on Tuesday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright also issued estimates for Kyverna Therapeutics’ FY2024 earnings at ($2.56) EPS.

Kyverna Therapeutics Trading Down 0.2 %

NASDAQ KYTX opened at $10.48 on Tuesday. The firm has a 50 day moving average price of $11.14. Kyverna Therapeutics has a 1-year low of $6.75 and a 1-year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.28). During the same quarter in the previous year, the business earned ($12.10) earnings per share. On average, research analysts predict that Kyverna Therapeutics will post -3.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KYTX. Jennison Associates LLC purchased a new position in Kyverna Therapeutics in the 1st quarter worth approximately $34,743,000. Vanguard Group Inc. acquired a new stake in shares of Kyverna Therapeutics in the first quarter valued at approximately $6,563,000. StemPoint Capital LP purchased a new position in Kyverna Therapeutics during the first quarter worth approximately $1,018,000. Avoro Capital Advisors LLC acquired a new position in Kyverna Therapeutics during the first quarter worth $11,799,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in Kyverna Therapeutics in the 1st quarter valued at $23,093,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.